According to data from the National Health and Health Commission on July 9, the number of new births in 2016 reached 17.86 million, an increase of 7.92% over the previous year, forming a small peak. According to a survey data, domestic compliance There are about 90 million women in the two-child policy. Under the risk of maternal age, 28% still have fertility wishes. The huge market increase of domestic assisted reproductive drugs has attracted the attention of domestic and foreign manufacturers.
Medical research shows that follicular dysplasia syndrome caused by endocrine dysfunction accounts for 48.42% of all infertility causes, ranking first in the cause of female infertility. In addition to rational adjustment of menstruation and treatment, it is necessary to choose the ideal promotion. The ovulation program promotes follicular development and maturity to achieve the purpose of conception. The advancement of modern medical drug research has solved some of the problems and promoted the development of the gonadotropin market.
pattern
Four major components of the female hormone market
After the introduction of the National Fertility Policy New Deal, the market for sex hormone drugs has responded, and the market for infertility treatment and the IVF-assisted reproductive technology market have attracted much attention.
According to the data of Mine Net, the amount of female hormones in public hospitals in key cities in China reached 1.88 billion yuan in 2017, a year-on-year growth rate of 5.09%. The estimated domestic market for assisted reproductive drugs has exceeded 15 billion yuan.
The clinical female hormone market consists of four parts, of which the dominant gonadotropin occupies 60.58%, the progesterone occupies 21.91%, the estrogen occupies 6.52%, and the contraceptive and androgen occupies 10.99%.
domestic enterprise Trying to capture the high-end market
At present, in the end-reproductive and sex hormone end market, bio-engineered drugs have replaced the trend of small-molecule drugs. Macromolecular products recombinant human follicle stimulating hormone, recombinant follicle-stimulating hormone β, recombinant human chorionic gonadotropin and human luteinizing hormone α gradually expanded .
In the structure of assisted reproductive end market, small molecule drugs are still the basis of assisted reproductive drugs. On February 2, 2018, Zhengda Tianqing's acetic acid and ganirelix injection was successfully listed, breaking the situation of Merck's exclusive market, perfecting In vitro, vaccination, control of ovulation with GnRH antagonist drug pattern, formed a sirolimus, Ganelix and GnRH agonist leuprolide.
Overall analysis, assisted reproductive drugs are basically oligopolistic markets, foreign manufacturers Merck Serono, Merck, and Huiling hold most of the market, while domestic Livzon Group, Kinsey Pharmaceuticals and other cities attack the city, aiming at import substitution. Domestic hormonal manufacturers Zhejiang Xianyu, Shenzhen Hanyu, Zhejiang Aisheng, Nanjing Xinbai, Yantai Dongcheng North Pharmaceutical also rapid growth, will open a breakthrough in the evaluation of generic drug consistency, thereby capturing the high-end market for assisted reproductive drugs and sex hormones.
Variety
Gonadotropin
Imported drugs account for a relatively high proportion
In the past five years, the key cities in China have been public hospital The market for female hormones has doubled, and gonadotropins are the first in the market for female hormones. According to the data from the intranet, the amount of gonadotropins in public hospitals in major cities in China was 1.154 billion yuan in the previous year. Under the influence of the annual stock market, the increase is small.
Gonadotropin is a glycoprotein hormone that regulates gonadal development and promotes the production and secretion of sex hormones. It synergizes with luteinizing hormone and follicle-stimulating hormone to stimulate the development of germ cells and sex hormones in the ovary or testis.
The gonadotropin TOP10 varieties in public hospitals in key cities in China are ranked according to the terminal purchase amount: recombinant human follicle stimulating hormone, triptorelin, urinary follicle stimulating hormone, urinary stimulating hormone, recombinant follicle stimulating hormone β, cetrorelix, oxytocin, Carbetocin, recombinant human chorionic gonadotropin and human luteinizing hormone α. Clinical drug characteristics are as follows: high proportion of imported drugs, more biological products, at their own expense drug many.
Domestic recombinant human follicle stimulating hormone accelerates
Recombinant human follicle stimulating hormone is mainly used for the treatment of infertility, non-ovulation and polycystic ovary syndrome. The original imported drug is the brand name of the German Merck Serono 'Gua Naifen'. The original CFDA approved in 2015. The recombinant human follicle stimulating hormone for injection developed by Jinsai Pharmaceutical Co., Ltd., a subsidiary of Changchun High-tech Co., Ltd., broke the situation that imported drugs dominated the world.
In 2017, the amount of recombinant follicle stimulating hormone in public hospitals in key cities in China was 358 million yuan, of which Merck Serono's 'Gonafin' was 345 million yuan, down 4.71% from the previous year. The amount of recombinant human follicle stimulating hormone in public hospitals in key cities was 12.57 million yuan, an increase of 16.44% over the previous year. With the advancement of domestically produced drugs in Changchun Jinsai, it will gradually replace imported drugs.
Progesterone
Progesterone ranks first
Progesterone, estrogen and androgen constitute the three major hormones of sex hormones. According to the data from the intranet, the amount of progesterone used in public hospitals in key cities in China was 417 million yuan in 2017, an increase of 1.61% over the previous year. Among them, the TOP5 variety is progesterone. , dydrogesterone, megestrol, medroxyprogesterone and allylestrenol.
The first drug in the progesterone market is progesterone. Progesterone is a clinically used variety for many years, also known as progesterone. Progesterone is a hormone that protects the female endometrium, providing support and guaranteeing the early growth and development of the fetus. , plays an important role in synergizing estrogen to promote the development of secondary sexual characteristics.
According to the data of the intranet, the amount of progesterone used in public hospitals in key cities in China was 216 million yuan in 2017, an increase of 5.57% over the previous year. TOP5 manufacturers are: Merck Serono accounts for 61.71%, Zhejiang Xianyu accounts for 16.90%, Apricot company accounted for 11.40%, Zhejiang Aisheng accounted for 6.24%, and Zhejiang Xinchang accounted for 2.02%. Progesterone dosage forms were more. In the sample hospital, progesterone gel accounted for 62.22%, capsules accounted for 31.64%, and injections accounted for 6.12%. Suppositories accounted for 0.02%.
Progesterone accounts for 50% of the pharmacy progesterone retail market
Progesterone is pharmacy The fast-growing progesterone variety in the retail market. According to the data from the intranet, the sales of progesterone in retail pharmacies in key cities in China was 42.3 million yuan in 2016, an increase of 80.73% over the previous year, which is the rapid growth of the domestic retail market for assisted reproductive drugs. 3. Drugs account for 50% of the pharmacy progesterone retail market.
The top 5 manufacturers of progesterone in the pharmacy retail market are: Merck Serono 34.24%, Zhejiang Aisheng 26.25%, Zhejiang Xianyu 21.99%, and French Apricot 12.84%, Zhejiang medicine Xinchang Pharmaceuticals accounted for 4.16%. In the pharmacy retail market, progesterone capsules accounted for 65.34%, gelatins accounted for 34.23%, and injections accounted for 0.43%.
Estrogen
The drug market is growing steadily
According to the data of the intranet, the amount of estrogen used in public hospitals in key cities in China was 124 million yuan in 2017, an increase of 9.37% over the previous year. In 2017, the amount of estrogen used in public hospitals in key cities in China was 140 million yuan, up from the previous year. 0.33%. TOP5 varieties are estradiol, estradiol dydrogesterone, ethinyl estradiol cyproterone, tibolone, estradiol valproate cyproterone. Currently used in estrogen drugs 2. It is a synthetic derivative of estradiol as a parent, such as estradiol benzoate, estradiol valerate, ethinyl estradiol, ethinyl estradiol, progesterone and so on.
